Northwire Canada EditionMonday, November 9, 2026
Sign inSubscribe
Northwire
⌕
Gold 4,138.60 +1.6% Silver 52.74 +1.6% Copper 6.33 +1.5% Oil 87.35 −3.8% Palladium 1,024.75 −9.2% UCU 2.14 +0.0% KAPA 0.105 +0.0% AFM 1.22 +0.0% BONE 0.040 +0.0% EM 4.30 +0.0% BKM 4.00 +0.0% SGO 0.150 +0.0% BNKR 2.62 +0.0% TECT 1.52 +0.0% MKA 0.650 +0.0% BEX 0.070 +0.0% RTH 0.035 +0.0% GBU 0.075 +0.0% KCC 0.840 +0.0% NEV 0.025 +0.0% FMAN 0.255 +0.0% Gold 4,138.60 +1.6% Silver 52.74 +1.6% Copper 6.33 +1.5% Oil 87.35 −3.8% Palladium 1,024.75 −9.2% UCU 2.14 +0.0% KAPA 0.105 +0.0% AFM 1.22 +0.0% BONE 0.040 +0.0% EM 4.30 +0.0% BKM 4.00 +0.0% SGO 0.150 +0.0% BNKR 2.62 +0.0% TECT 1.52 +0.0% MKA 0.650 +0.0% BEX 0.070 +0.0% RTH 0.035 +0.0% GBU 0.075 +0.0% KCC 0.840 +0.0% NEV 0.025 +0.0% FMAN 0.255 +0.0%
Production / Operations

Triera Biosciences - a Zentek Company - Launches Contract Research Organization Services for Custom Aptamer Discovery, Biosensor Enablement, and Machine-Learning Classification

Zentek pivots to high-margin CRO services as it fights to maintain Nasdaq listing and de-risk its nuclear-grade graphite asset.

By The Northwire Desk — AI Analysis Mar 25, 2026 · 08:30 ZEN · 0.8 Zentek Ltd.
Executive Summary

The most recent news (March 25, 2026) announces that Zentek’s subsidiary, Triera Biosciences, is launching Contract Research Organization (CRO) services. This move transitions Triera from a pure-play R&D house into a service provider for the pharmaceutical and biotech industries. The services include custom aptamer discovery (via SELEX), biosensor engineering, and machine-learning (ML) classification. This initiative leverages a 20-year exclusive license from McMaster University. Management expects this to generate "earlier and more predictable revenue" to fund internal product development.

Material Impact

The impact is Material - Positive for three reasons: - Revenue Generation: Historically, Zentek has been a high-burn R&D company (Net Loss of $6.2M in the quarter ended Dec 2025). Transitioning to a CRO model provides a path to non-dilutive cash flow, which is critical given the current cash balance of only $1.8M. - Market Validation: By offering services to third parties, Zentek validates its proprietary aptamer platform. The target markets (Influenza, Syphilis, VEGF) represent multi-billion dollar diagnostic opportunities. - Strategic Focus: This follows the "Strategic Reset" announced in January 2026, showing execution on the promise to focus on core platforms (Albany, ZenGUARD, Triera) while seeking "credible cashflow opportunities."

ZEN · Price
Company Overview

Zentek is an IP-development company. Its flagship mining asset is the Albany Graphite Project in Ontario, a unique igneous-hosted deposit. Recent testing (Jan 2026) confirmed it meets "nuclear-grade" purity (99.9992%), which is a significant differentiator from standard battery-grade graphite. The company also owns ZenGUARD (antimicrobial coatings) and Triera Biosciences (aptamer-based diagnostics/therapeutics).

Read the original news release →

More from Zentek Ltd.

Oct 26, 2026 · 06:01

Zentek withdraws from Nasdaq, rejecting share consolidation to preserve capital.

Regulatory Oct 05, 2026 · 07:25

Zentek advances nuclear graphite purification, though a massive capital expenditure gap remains unresolved for the project.

Production / Operations Oct 01, 2026 · 07:41

Zentek’s first federal order validates ZenGUARD filters, though revenue impact remains marginal.

Other Sep 24, 2026 · 07:41

Zentek filed the Albany PEA confirming a $3.85bn NPV and 27.4% IRR for its nuclear-grade graphite project.

Technical Study Sep 16, 2026 · 07:36

Zentek has been pre-qualified for Canadian defence drone coatings, although no committed orders have been secured to date.

Other Sep 14, 2026 · 07:31

Albany Graphite achieves 5N+ purity and secures its first Canadian government orders for the ZenGUARD product line.

Production / Operations